STShakila Thangaratinam

Shakila Thangaratinam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shakila Thangaratinam has a total of 759 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cardiovascular health across the life course: a roundtable discussion

    by Babu Karavadra, Ann McArdle, Naheed Tahir, Stephanie Tomlinson, Shakila Thangaratinam

  • Open Access

    Which Is The Best Method For Induction Of Labour In Low- And Middle-Income Countries?: A Systematic Review And Network Meta-Analysis

    by Victoria Bradley, Alexandra Hunt, Flora Jobson, Rachel Greenwood, Mahmoud Aljubeh, Mohamed Okba, Freddy Fayers, Eve Bunni, Carol Kingdon, Address Malata, et al.

    Background: Globally, induction of labour rates and methods vary according to resource setting. Our aim is to identify the most effective induction of labour method for achieving vaginal birth within 24 hours in low- and middle-income settings without increasing adverse outcomes.Methods: We searched Embase, Medline, Scopus, African Journals Online, CINAHL, Web of Science, Epistemonikos and Cochrane Central to August 2025 with no language restrictions. We included RCTs conducted in LMICs that compared any induction method to placebo or another induction method. We conducted a network meta-analysis using a Bayesian framework and ranking using odds ratios. The relative treatment efficacy ranking of the interventions was determined using the area under the cumulative ranking curve (SUCRA) values. Only trials with low risk of bias were included in the primary analysis.Findings: 207 studies were included (78 low risk, 37 moderate risk, 92 high risk) reporting outcomes for 37, 280 women and 60 induction methods. Low dose oral misoprostol is likely to be the most effective method for achieving vaginal birth within 24 hours (oral misoprostol <50 micrograms vs vaginal misoprostol <50 micrograms OR = 3.36, 95% Credible Interval (CrI) 1.25, 9.95), without increasing the caesarean birth rate (OR 0.98, 95% CrI 0.68, 1.48), NICU admission (OR 0.56, 95% CrI 0.24, 1.18) or Apgar scores <7 at 5 minutes (OR 0.50, 95% CrI 0.10, 2.31). However, compared with vaginal misoprostol<50 micrograms, oral misoprostol <50 micrograms may increase the chance of maternal side-effects including diarrhoea (OR =13.71, 95% CrI 1.44, 381.36) and nausea and vomiting (OR = 2.68, 95% CrI 1.44, 5.26).Interpretation: Low dose oral misoprostol appears to be most efficacious for achieving vaginal birth within 24 hours without increasing the incidence of adverse outcomes. For each woman selecting the best induction method involves a tradeoff between effectiveness, side-effects risks and benefits.

  • Open Access

    The effect of lifestyle interventions in women with polyendocrine metabolic ovarian syndrome: A systematic review and meta-analysis

    by Oladipupo Olalere, Min-Dee Koh, Katie Crabb, Olanike Ajijola, Saba Tariq, Chau Thien Tay, Aya Mousa, Soha Sobhy, Lynne Robinson, Rima Dhillon-Smith, et al.

    Background: Lifestyle interventions are recommended as first-line treatment in polyendocrine metabolic ovarian syndrome (PMOS), but their effectiveness across various outcomes remains unclear. In this systematic review, we evaluate the effectiveness of lifestyle interventions on reproductive, anthropometric, and metabolic outcomes. Methods and findings: We searched Medline, EMBASE, All EBM, PsycInfo, and CINAHL to June 2026 for studies examining lifestyle intervention compared with minimal or no treatment (usual care) in PMOS. Meta-analyses were conducted using random-effects model to estimate pooled odd ratios (OR) with 95% confidence intervals (CI). We conducted subgroup analyses to evaluate differences by intervention type and duration, and by baseline body mass index (BMI). A total of 34 studies (1,871 participants) were included from the retrieved 1,798 publications. Women who participated in lifestyle interventions were more likely to achieve regular menstrual cycles OR 4.03 (95% CI [1.16, 14.05] I 2 = 73%, 5 studies, 237 women), and have reduced waist circumference mean difference (MD) −2.38 (95% CI [−4.68, −0.08] I 2 = 90%, 18 studies, 915 women), fasting glucose MD −0.13 (95% CI [−0.25, −0.02] I 2 = 86%, 22 studies, 1,045 women) and fasting insulin MD −6.08 (95% CI [−9.86, −2.30] I 2 = 71%, 18 studies, 824 women) compared to women who had minimal or no treatment. Subgroup analyses showed that diet interventions had greater effect on reducing fasting glucose levels while exercise was most effective at reducing waist circumference and fasting insulin. In women with PMOS who were overweight or obese, lifestyle interventions led to greater reduction in weight, waist/hip ratio, fasting glucose, fasting insulin, total testosterone, total cholesterol, and low-density lipoprotein. The main limitation of this review is the high between-study heterogeneity in pooled estimates across many of the outcomes. Conclusion: Our review found that lifestyle interventions were associated with improved menstrual regularity and metabolic outcomes in women with PMOS, suggesting complementary benefits as no single intervention showed overall superiority. These findings support international recommendations, which endorse lifestyle interventions as first-line treatment, tailored to individual needs.


  • Open Access

    Prognostic value of cervical length for spontaneous preterm birth in asymptomatic women with singleton pregnancy: An individual participant data meta-analysis

    by Kelly Hughes, David Nguyen, Mason Aberoumand, Heather Ford, Erin Clarke, Nuria Banos Lopez, Margaret Dziadosz, Richard Fischer, Renato T. Souza, Jose Guilherme Cecatti, et al.

    Background: Spontaneous preterm birth (SPTB) is the leading cause of perinatal and early childhood mortality worldwide. Studies have generally suggested that mid-trimester transvaginal sonographic cervical length n = 91,404). Mean cervical length was 40 mm (standard deviation [SD] 9 mm) at about 20 weeks’ gestation. SPTB <37 weeks occurred in 4,442 (5.2%) participants. An L-shape non-linear association between cervical length and SPTB was observed. A longer cervical length was associated with steeply lower odds of SPTB until it reached 40 mm, beyond which the odds of SPTB became stable. This means that compared to a woman with a cervical length of 40 mm, those with a cervical length of 20 and 30 mm were associated 6.22 and 2.10 higher odds of SPTB (95% confidence intervals [4.76, 8.13] and [1.85, 2.38]), respectively. Limitations included suboptimal data retrieval rate (51% of all eligible participants) and a lack of comprehensive co-predictors of SPTB across all datasets. Conclusion: We found a non-linear association between cervical length and SPTB. We found a non-linear association between cervical length and SPTB. Shorter cervix is associated with progressively higher risk of SPTB when length is less than 40 mm, but probability of term birth is high when cervical length is over 40 mm.

  • Top Cited Papers
    Open Access

    Maternal paracetamol (acetaminophen) use during pregnancy and risk of autism spectrum disorder and attention deficit/hyperactivity disorder in offspring: umbrella review of systematic reviews

    by Jameela Sheikh, John Allotey, Soha Sobhy, Maria Nieves Plana, Hilario Martinez-Barros, Harshitha Naidu, Fatima Junaid, Reecha Sofat, Ben W Mol, Louise C Kenny, et al.

    Objective To assess the quality, biases, and validity of evidence on maternal paracetamol (acetaminophen) use during pregnancy and the risk of autism spectrum disorder (referred to as autism) and attention deficit/hyperactivity disorder (ADHD) in offspring. Design Umbrella review of systematic reviews. Data sources Medline, Embase, PsycINFO, and the Cochrane Database of Systematic Reviews, along with grey literature, Epistemonikos, and the reference lists of included studies (inception to 30 September 2025). Inclusion criteria Systematic reviews of randomised trials and cohort, case-control, or cross sectional studies that reported maternal paracetamol use during pregnancy and the diagnosis of autism or ADHD in offspring. Details of the primary studies included in the reviews are reported, including adjustments for key confounders (maternal characteristics, indication for paracetamol use, and familial factors) and unmeasured confounders and ascertainment of outcomes. Results Nine reviews (40 studies) reporting on autism (six studies) and ADHD (17 studies) in offspring were included. Four reviews undertook meta-analysis. The overlap of primary studies included in the reviews was very high (corrected covered area 23%). The reviews reported a possible to strong association between maternal paracetamol intake and autism or ADHD or both in offspring. Seven of the nine reviews advised caution when interpreting the findings owing to the potential risk of bias and confounding in the included studies. Confidence in the findings of the reviews was low (two reviews) to critically low (seven reviews) based on the AMSTAR 2 (A MeaSurement Tool to Assess Systematic Reviews) criteria. Only one review included studies (n=2) reporting autism and ADHD in offspring that appropriately adjusted for familial factors and unmeasured confounding through sibling controlled analyses. In both studies, the increased risk of autism in offspring (one study, hazard ratio 1.05, 95% confidence interval 1.02 to 1.08) and ADHD (two studies, 1.07, 1.05 to 1.10 and 2.02, 1.17 to 3.25 ) observed in the whole cohort analyses did not persist in sibling controlled analyses for autism (0.98, 0.93 to 1.04) and ADHD (0.98, 0.94 to 1.02 and 1.06, 0.51 to 2.05). Conclusion Existing evidence does not clearly link maternal paracetamol use during pregnancy with autism or ADHD in offspring. Systematic review registration PROSPERO CRD420251154052.


  • Open Access

    Associations between epileptic seizures in pregnancy and adverse pregnancy outcomes: A systematic review and meta-analysis

    by Oladipupo Olalere, Saba Tariq, Olanike Ajijola, Min-Dee Koh, Katie Crabb, Amie Wilson, Anwesa Chatterjee, Mairead Black, Katie Morris, Matthew Bluett-Duncan, et al.

    Background: Epileptic seizures during pregnancy may increase the risk of adverse pregnancy outcomes. Socioeconomic disparities in epilepsy incidence may extend to seizure control. We conducted a systematic review and meta-analysis to assess the association between epileptic seizures during pregnancy and adverse pregnancy outcomes. We also evaluated the association between socioeconomic and individual-level factors and seizure occurrence. Methods and findings: We searched MEDLINE, Embase, CINAHL, and PsycINFO databases from inception to May 2025 for observational studies on pregnant women with epileptic seizures. We compared maternal and foetal outcomes in pregnant women with and without seizures and assessed the association between seizure occurrence and socioeconomic or individual-level factors. We used the Newcastle–Ottawa Scale to assess the risk of bias of included studies. Meta-analyses using random effects model were performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs). From 13,381 identified publications, 25 studies (24,596 pregnancies) are included in this analysis. In pregnant women with epilepsy, women with seizures compared to those without had increased odds of caesarean birth (OR 1.62, 95% CI 1.14 to 2.30, p = 0.007), peripartum depression (OR 2.20, 95% CI 1.04 to 4.65, p = 0.04), and small for gestational age baby (OR 1.32, 95% CI 1.03 to 1.69, p = 0.03). The odds of preterm birth (OR 1.66, 95% CI 1.29 to 2.15, p < 0.001), low birthweight (OR 1.47, 95% CI 1.12 to 1.93, p = 0.006), and small for gestational age baby (OR 1.44, 95% CI 1.19 to 1.74, p < 0.001) were higher in women with seizures compared to women without epilepsy. The risk of seizures was greater in pregnant women with epilepsy with low income compared to those with higher income (OR 1.57, 95% CI 1.22 to 2.02, p < 0.001), and in women with focal epilepsy compared to those with generalised epilepsy (OR 1.84, 95% CI 1.54 to 2.20, p < 0.001). The number of studies for some outcomes was small, limiting subgroup analyses and detection of heterogeneity. Conclusion: Epileptic seizures are associated with increased risks of adverse maternal and foetal outcomes. Risk assessment to identify women with epilepsy at highest risk of seizures is needed to optimise care.


  • Open Access

    Effects of maternal education on maternal and perinatal outcomes: An individual participant data meta‐analysis of 2 356 402 pregnancies

    by Laura‐Margarita Bello‐Álvarez, Borja M. Fernández‐Félix, Jhon Allotey, Shakila Thangaratinam, Javier Zamora

    Background: Maternal and perinatal mortality remain critical indicators of global health inequity. In 2020, an estimated 287 000 women died from preventable causes related to pregnancy, and in 2021, approximately 2.3 million neonatal deaths occurred within the first 28 days of life. A recently defined risk group, small vulnerable newborns (SVNs, including preterm, low birth weight, and small‐for‐gestational‐age infants), highlights the compounded vulnerability of certain newborns. Maternal education is a key social determinant of health, yet its effect on maternal and perinatal outcomes across global settings remains insufficiently quantified. Aims: The primary aim of this study was to quantify the association between maternal education level and adverse maternal and perinatal outcomes. The secondary aim was to evaluate whether these associations vary by country income level. Methods: We conducted an individual participant data (IPD) meta‐analysis using data from the International Prediction of Pregnancy Complications (IPPIC) Network. Eligible studies included those reporting maternal and perinatal outcomes stratified by at least two levels of maternal education (informal/primary, secondary, tertiary). Primary outcomes were maternal mortality, preeclampsia, stillbirth, and SVNs. Associations were estimated using a two‐step random‐effects IPD meta‐analysis adjusted for maternal age and ethnicity. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported. Results: Compared to tertiary education, women with secondary education had a 27% higher risk of maternal death (OR 1.27, 95% CI 0.38; 4.30), and those with informal or primary education had approximately double the risk (OR 2.51, 95% CI 0.23; 26.95). Risk of stillbirth was also twofold higher in lower education groups. These association remained significant in analyses restricted to high‐income countries. Discussion: Women with lower levels of education are at substantially greater risk of adverse maternal and perinatal outcomes. These findings reinforce the need for education‐focused policy and health system strategies to reduce maternal and neonatal mortality, particularly in settings with high educational inequality.


  • Open Access

    FERN: is it possible to conduct a randomised controlled trial of intervention or expectant management for early-onset selective fetal growth restriction in monochorionic twin pregnancy – protocol for a prospective multicentre mixed-methods feasibility study

    by Asma Khalil, Smriti Prasad, Kerry Woolfall, Tracy Karen Mitchell, Jamie J Kirkham, Odai Yaghi, Tracey Ricketts, George Attilakos, Carolyn Bailie, Christine Cornforth, et al.

    Introduction Selective fetal growth restriction (sFGR) in monochorionic twin pregnancy, defined as an estimated fetal weight (EFW) of one twin Methods and analysis The FERN study is a prospective mixed-methods feasibility study. The primary objective is to recommend whether an RCT of intervention vs expectant management of sFGR in monochorionic twin pregnancy is feasible by exploring women’s preference, clinician’s preference, current practice and equipoise and numbers of cases. To achieve this, we propose three distinct work packages (WPs). WP1: A Prospective UK Multicentre Study, WP2A: a Qualitative Study Exploring Parents’ and Clinicians’ Views and WP3: a Consensus Development to Determine Feasibility of a Trial. Eligible pregnancies will be recruited to WP1 and WP2, which will run concurrently. The results of these two WPs will be used in WP3 to develop consensus on a future definitive study. The duration of the study will be 53 months, composed of 10 months of setup, 39 months of recruitment, 42 months of data collection, and 5 months of data analysis, report writing and recommendations. The pragmatic sample size for WP1 is 100 monochorionic twin pregnancies with sFGR. For WP2, interviews will be conducted until data saturation and sample variance are achieved, that is, when no new major themes are being discovered. Based on previous similar pilot studies, this is anticipated to be approximately 15–25 interviews in both the parent and clinician groups. Engagement of at least 50 UK clinicians is planned for WP3. Ethics and dissemination This study has received ethical approval from the Health Research Authority (HRA) South West—Cornwall and Plymouth Ethics Committee (REC reference 20/SW/0156, IRAS ID 286337). All participating sites will undergo site-specific approvals for assessment of capacity and capability by the HRA. The results of this study will be published in peer-reviewed journals and presented at national and international conferences. The results from the FERN project will be used to inform future studies. Trial registration number This study is included in the ISRCTN Registry (ISRCTN16879394) and the NIHR Central Portfolio Management System (CPMS), CRN: Reproductive Health and Childbirth Specialty (UKCRN reference 47201).


  • Open Access

    Development and validation of a prognostic model to predict birth weight: individual participant data meta-analysis

    by John Allotey, Lucinda Archer, Kym I E Snell, Dyuti Coomar, Jacques Massé, Line Sletner, Hans Wolf, George Daskalakis, Shigeru Saito, Wessel Ganzevoort, et al.

    Objective: To predict birth weight at various potential gestational ages of delivery based on data routinely available at the first antenatal visit. Design: Individual participant data meta-analysis. Data sources: Individual participant data of four cohorts (237 228 pregnancies) from the International Prediction of Pregnancy Complications (IPPIC) network dataset. Eligibility criteria for selecting studies: Studies in the IPPIC network were identified by searching major databases for studies reporting risk factors for adverse pregnancy outcomes, such as pre-eclampsia, fetal growth restriction, and stillbirth, from database inception to August 2019. Data of four IPPIC cohorts (237 228 pregnancies) from the US (National Institute of Child Health and Human Development, 2018; 233 483 pregnancies), UK (Allen et al, 2017; 1045 pregnancies), Norway (STORK Groruddalen research programme, 2010; 823 pregnancies), and Australia (Rumbold et al, 2006; 1877 pregnancies) were included in the development of the model. Results: The IPPIC birth weight model was developed with random intercept regression models with backward elimination for variable selection. Internal-external cross validation was performed to assess the study specific and pooled performance of the model, reported as calibration slope, calibration-in-the-large, and observed versus expected average birth weight ratio. Meta-analysis showed that the apparent performance of the model had good calibration (calibration slope 0.99, 95% confidence interval (CI) 0.88 to 1.10; calibration-in-the-large 44.5 g, −18.4 to 107.3) with an observed versus expected average birth weight ratio of 1.02 (95% CI 0.97 to 1.07). The proportion of variation in birth weight explained by the model (R2) was 46.9% (range 32.7-56.1% in each cohort). On internal-external cross validation, the model showed good calibration and predictive performance when validated in three cohorts with a calibration slope of 0.90 (Allen cohort), 1.04 (STORK Groruddalen cohort), and 1.07 (Rumbold cohort), calibration-in-the-large of −22.3 g (Allen cohort), −33.42 (Rumbold cohort), and 86.4 g (STORK Groruddalen cohort), and observed versus expected ratio of 0.99 (Rumbold cohort), 1.00 (Allen cohort), and 1.03 (STORK Groruddalen cohort); respective pooled estimates were 1.00 (95% CI 0.78 to 1.23; calibration slope), 9.7 g (−154.3 to 173.8; calibration-in-the-large), and 1.00 (0.94 to 1.07; observed v expected ratio). The model predictions were more accurate (smaller mean square error) in the lower end of predicted birth weight, which is important in informing clinical decision making. Conclusions: The IPPIC birth weight model allowed birth weight predictions for a range of possible gestational ages. The model explained about 50% of individual variation in birth weights, was well calibrated (especially in babies at high risk of fetal growth restriction and its complications), and showed promising performance in four different populations included in the individual participant data meta-analysis. Further research to examine the generalisability of performance in other countries, settings, and subgroups is required. Trial registration: PROSPERO CRD42019135045